EGFR and non-small cell lung carcinoma: FLAURA was a Phase III, double-blind, randomized study assessing efficacy and safety of osimertinib versus standard of care EGFR-TKI (gefitinib or erlotinib) in the first-line treatment of patients (n = 556) with Ex19del/L858R EGFR mutated advanced NSCLC [21].